PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26089640-1	2015	AT-101 is a BH3 mimetic and pan-Bcl-2 inhibitor that has shown potent anticancer activity in non-small-cell lung cancer (NSCLC) in murine models, but failed to show clinical efficacy when used in combination with docetaxel in NSCLC patients.	gossypol acetic acid	0-6	B cell leukemia/lymphoma 2	Mus musculus	32-37	
26113054-1	2015	PURPOSE: AT-101 is considered as a putative pan-inhibitor of anti-apoptotic Bcl-2 family protein members acting as a BH3 mimetic.	gossypol acetic acid	9-15	B cell leukemia/lymphoma 2	Mus musculus	76-81	
18292288-3	2008	AT-101 is a BH3 mimetic known to be a potent inhibitor of antiapoptotic Bcl-2 family members including Bcl-2, Bcl-X(L), and Mcl-1.	gossypol acetic acid	0-6	B cell leukemia/lymphoma 2	Mus musculus	72-77	
18292288-3	2008	AT-101 is a BH3 mimetic known to be a potent inhibitor of antiapoptotic Bcl-2 family members including Bcl-2, Bcl-X(L), and Mcl-1.	gossypol acetic acid	0-6	B cell leukemia/lymphoma 2	Mus musculus	103-108